Gujarat Themis Biosyn Ltd Guidance Report - SOIC x StockScans Report
as of Nov 2026
- Amalgamation with Themis Medicare - scheme announced
Missed - In November 2024, the company announced a scheme of amalgamation of Gujarat Themis Biosyn Ltd with Themis Medicare Ltd. At the Q1 FY27 call, management explained the scheme was withdrawn about 6 months later, with the decision instead to grow GTBL as a fermentation-based CDMO; no amalgamation was completed.
- Free cash flow - combined entity ₹90-100 crores, GTBL side ₹15-20 crores
Pending - At the Q2 FY27 call, the CFO guided free cash flow of "easily around 90 to 100 crores" (after interest) for the combined entity, excluding further acquisitions and incremental capex, and "around 15 to 20 crores" from the GTBL side. No disclosure of FCF against these ranges has yet been made in our record.
- High-teens base-case growth - over next 3-5 years
On track - At the Q1 FY27 call, management said on a base case they want to grow on a "high-teen basis", declining to specify an absolute top-line number for the next 3-5 years. Q1 FY27 revenue grew 22.1% YoY, Q2 FY27 standalone revenue grew 12% YoY and H1 FY27 grew 17% YoY; the 3-5 year horizon has not elapsed.
- Promoter pledge reduction - significantly down within 12-15 months
Pending - At the Q1 FY27 call, management said promoter pledge/encumbrance "within a year, it should be going down... 12 to 15 months should be going down significantly". No disclosure of pledge levels or any reduction has yet been made; the horizon (June-September 2027) has not elapsed.
- Equity raise - up to ₹1,000 crores via QIP
Partial - At the Q1 FY27 call, management said they had decided to raise equity up to ₹1,000 crores, with July 2026 announcements confirming a ₹1,000 crore QIP in process. GTBL raised ₹750 crore via preferential issue, with the QIP at ₹727 crore; at Q2 FY27 management said NCDs would fall via a preferential issue of "about 300-odd crores" without going to the equity market, and QIP proceeds were utilized within limits per the monitoring agency report.
- Sanofi brands acquisition - close by end of Q3 FY27
On track - Announcement of 23 April 2026 guided the transaction to close by end of Q3 FY27 (31 December 2026); at the Q1 FY27 call management said closing was 6 to 9 months away, "if not longer", with a long stop date of June 2027. As of Q2 FY27, the deal remained pending regulatory approvals from over 50 countries, with clearances expected January-February 2027.
- MBJ acquisition - close by August end 2026
Delivered - At the Q1 FY27 call, management said the MBJ deal was expected to close by August end 2026, with funding "pretty much" secured; the Q4 FY26 PPT had guided closing in Q2 FY2027. The acquisition completed on 18 September 2026 for a total purchase consideration of ₹1,351 crores, and MBJ was consolidated for 13 days in Q2 FY27.
- Hybrid power plant - 18.45 MW, Phase 1 live September 2026, full project by December 2026
On track - At the Q1 FY27 call, management said Phase 1 would go live in September 2026 with the second phase two months later, improving EBITDA margins. On 9 October 2026 the first phase was commissioned - 9 MW solar and one 3.15 MW wind turbine - taking the plant to 12.15 MW as of 16 November 2026, with Wind Turbine 2 planned November 2026 and Wind Turbine 3 plus Commencement Certificate December 2026; the plant is expected to halve energy cost.
- FY24 revenue growth of 25-30% - to ₹190-200 crores
Missed - At the Q3 FY23 call, management expected 25% to 30% growth in FY24 versus FY23, helped by the new API block; at Q4 FY23 they declined to guide, and at Q2 FY24 said reaching ₹200 crores "will not happen this year". FY24 revenue was ₹169.82 crores, up 14.45% YoY - below both the growth range and the ₹190-200 crores range.
- NSE listing - once net worth over ₹100 crores for 3 consecutive years
Missed - At the Q2 FY23 call, management said the company should "most definitely" list on NSE once net worth exceeded ₹100 crores for 3 consecutive years, with the third year "gets over next year". No NSE listing has been disclosed in any subsequent filing or call; the interim period saw a share subdivision effective 11 October 2023, a 1:2 bonus in FY25, and a merger scheme announced then withdrawn.
- API block - online end of Q2 FY2024, first API commercialization Q1 FY25
Missed - At the Q2 FY23 call, management guided the API block online at "end of Q2 FY2024" at a cost of about ₹40 crores, later revised to September 2023 with first commercialization "certainly Q1 of next year", then December 2023 and October 2023. Production began May 2025; at Q1 FY27 management admitted the FY25 API revenue had not materialized, with quarterly revenue still around the historic ₹40 crores run rate and API production "has just begun now".
- ₹200+ crore capex programme - new products, R&D, API block, fermentation expansion - phased over 2-3 years from FY23
Partial - At the Q2 FY22 call, management guided capex "in the vicinity of about 200-plus crores" over two to three years, reiterated at Q2 FY23 as ₹200 crores from FY23 funded through internal accruals. Gross block grew from \~₹62 crores in FY23 to \~₹435 crores in FY26 including CWIP; R&D Phase 1 was commissioned by Q3 FY24, the API block began production May 2025, the new fermentation block doubled capacity to 990 KL in October 2025, and hybrid power plant Phase 1 was commissioned 9 October 2026 - with management admitting at Q1 FY27 the company was "late by almost about a year".